# Mass Screening Strategies for Celiac Disease in Apparently Healthy Children and Adolescents: A Systematic Review

**Authors:** Alexandra Mpakosi, Vasileios Cholevas, Andreas G. Tsantes, Argyro Pastrikou, Aikaterini Fragkiadaki, Sofia Zhgabi, Vasiliki Mougiou, Nicoletta Iacovidou, Rozeta Sokou

PMC · DOI: 10.3390/medicina62020246 · 2026-01-24

## TL;DR

This review examines global mass screening strategies for celiac disease in healthy children and adolescents, analyzing their effectiveness, accuracy, and outcomes.

## Contribution

The study systematically reviews global mass screening programs for celiac disease in asymptomatic children, evaluating their diagnostic accuracy, cost-effectiveness, and long-term benefits.

## Key findings

- Celiac disease seroprevalence in healthy children ranged from 0.20% in Turkey to 3.11% in Italy.
- Rapid finger-prick tests showed comparable accuracy to other screening methods but require further validation.
- Follow-up data showed improved health outcomes after adopting a gluten-free diet.

## Abstract

Background and Objectives: Celiac disease (CD) is a major global public health problem that can occur at any age. Pediatric CD can be typical, atypical, or even asymptomatic. Early diagnosis and early initiation of treatment are essential for improving patients’ quality of life and preventing serious complications later in life. However, it is impossible to identify asymptomatic children and adolescents without screening. In this systematic review, we attempted to identify different mass screening programs that have been reported for CD in apparently healthy children and adolescents across the world, to highlight the advantages and disadvantages of such strategies, and to collect and synthesize data from these studies reporting the prevalence of CD. In addition, where data were available, we also attempted to evaluate the diagnostic accuracy of the tests used, their cost-effectiveness, the reported clinical benefits, and follow-up data from individuals identified through screening. Materials and Methods: Electronic databases, including PubMed and Scopus, were systematically searched. Initially, a total of 316 studies were retrieved. Finally, 55 studies met all inclusion criteria and were included in this review. The included studies were published between 1996 and 2023. Results: The reported age of participants ranged from 6 months to 23 years. Confirmation of CD by biopsy was reported in all but six studies. According to the studies that provided data, the (tTG IgA) seroprevalence of CD in apparently healthy children and adolescents, detected through different mass screening methods around the world, ranged from 0.20% (Turkey) to 3.11% (Italy). In addition, the prevalence of biopsy-confirmed CD ranged from 0.036% (Vietnam) to 3% (Sweden and Spain). Studies from 17 countries reported mass screening strategies based on finger-prick rapid tests. All rapid tests detected CD antibodies, except two, which detected HLA DQ2/DQ8 haplotypes. Rapid tests appeared to be no less sensitive and specific than other screening tests for CD and were probably less expensive, but further studies are needed for more reliable conclusions. Of the 55 studies in the review, only 10 reported follow-up data. After 3 months of a gluten-free diet, the general condition of the patients improved; after 6 months, tTG IgA and EMA IgA levels decreased and hemoglobin values increased; while after 1 year, tTG IgG levels also decreased, symptoms subsided, the children’s weight and height increased, school performance improved, episodes of upper respiratory tract infections decreased, and thyreoperoxidase antibodies that were positive at screening became negative. Conclusions: Mass screening for CD in asymptomatic children and adolescents is a challenge. Future research should provide more answers regarding the most appropriate target age, the frequency of screening, the optimal screening method, the cost-effectiveness, the clinical utility, and the long-term impact of mass screening on patients’ quality of life.

## Linked entities

- **Diseases:** Celiac disease (MONDO:0005130)

## Full-text entities

- **Genes:** CD79A (CD79a molecule) [NCBI Gene 973] {aka IGA, IGAlpha, MB-1, MB1}, HLA-A (major histocompatibility complex, class I, A) [NCBI Gene 3105] {aka HLAA}, PRSS3 (serine protease 3) [NCBI Gene 5646] {aka MTG, PRSS4, T9, TRY3, TRY4}, TGM2 (transglutaminase 2) [NCBI Gene 7052] {aka G(h), TG(C), TGC, hTG2, tTG}, MUC1 (mucin 1, cell surface associated) [NCBI Gene 4582] {aka ADMCKD, ADMCKD1, ADTKD2, CA 15-3, CD227, Ca15-3}, AGA (aspartylglucosaminidase) [NCBI Gene 175] {aka AGU, ASRG, GA}
- **Diseases:** Celiac Disease (MESH:D002446), iron deficiency anemia (MESH:D018798), pernicious anemia (MESH:D000752), diarrhea (MESH:D003967), William-Beuren syndrome (MESH:D018980), autoimmune disorders (MESH:D001327), gastric autoimmunity (MESH:D013274), osteopenia (MESH:D001851), dental enamel defect (MESH:D000094602), anxiety (MESH:D001007), abdominal pain (MESH:D015746), vitiligo (MESH:D014820), adrenal insufficiency (MESH:D000309), cancer (MESH:D009369), Down or Turner syndrome (MESH:D004314), irritability (MESH:D001523), short stature (MESH:D006130), fractures (MESH:D050723), headache (MESH:D006261), inflammation (MESH:D007249), respiratory tract infections (MESH:D012141), coeliac disease (MESH:D004194), IgA deficiency (MESH:D017098), injury to (MESH:D014947), aphthous stomatitis (MESH:D013281), Turner syndrome (MESH:D014424), T1D (MESH:D003922), delayed puberty (MESH:D011628), depression (MESH:D003866), abdominal distension (MESH:D000007), autoimmune thyroid disease (MESH:D013967), osteoporosis (MESH:D010024), weight loss (MESH:D015431), bone loss (MESH:D001847), infertility (MESH:D007246), gastrointestinal disease (MESH:D005767), infections (MESH:D007239), hip and vertebral fractures (MESH:D006620), malnutrition (MESH:D044342), ataxia (MESH:D001259), dermatitis herpetiformis (MESH:D003874), epilepsy (MESH:D004827), arthritis (MESH:D001168), anemia (MESH:D000740)
- **Chemicals:** folate (MESH:D005492), DGP (-)
- **Species:** Meleagris gallopavo (common turkey, species) [taxon 9103], Homo sapiens (human, species) [taxon 9606]

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12942272/full.md

---
Source: https://tomesphere.com/paper/PMC12942272